Effects of Stimulant Treatment on Changes in Brain Activation During Reward Notifications in Drug Naïve Youth With ADHD.

Autor:	Ivanov I; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Krone B; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Schulz K; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Shaik RB; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Parvaz MA; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Newcorn JH; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jazyk:	angličtina
Zdroj:	Journal of attention disorders [J Atten Disord] 2024 Mar; Vol. 28 (5), pp. 847-860. Date of Electronic Publication: 2024 Jan 31.
DOI:	10.1177/10870547231219762
Abstrakt:	Background: Research examining the potential effects of stimulant exposure in childhood on subsequent development of substance use disorder (SUD) have focused on differences in the brain reward system as a function of risk. Methods: 18 drug naïve children ages 7 to 12 years (11 High Risk [ADHD + ODD/CD]; 7 Low Risk [ADHD only]), underwent fMRI scans before and after treatment with mixed amphetamine salts, extended release (MAS-XR). We examined correlations between clinical ratings and fMRI activation at baseline and following treatment as a function of risk status. Results: High Risk children had higher activation than Low Risk children at baseline during both the Reward and Surprising Non-Reward conditions. Treatment produced strong differential effects on brain activation pertinent to group and reward outcome. Conclusions: Findings support the hypothesized role of reward mechanisms in SUD risk, and suggest that stimulant treatment may have differential effects on reward processing in relation to SUD risk. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Iliyan Ivanov—no conflicts, Beth Krone—in the last 3 years was a consultant for Signant Health, Mind Tension, Hippo T&C, and Maxis Health, Kurt Schulz—no conflicts, Riaz Shaik—no conflicts, Muhammad Parvaz—no conflicts, Jeffrey Newcorn—in the last three years J.H.N. was a consultant/advisory board member for Adlon Therapeutics, Cingulate Therapeutics, Corium, Hippo T&C, Ironshore, Lumos, Medice, MindTension, Myriad, NLS, OnDosis, Otsuka, Rhodes, Shire/Takeda, Signant and Supernus; he received research support from Adlon, Otsuka, Shire, Supernus; honoraria for disease state lectures from Otsuka and Shire, and served as a consultant for the US National Football League.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu